Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati
The FDA approved the drug in 2022. Administered as chronic IV treatment.On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional commercial milestone payments of up to $250 million.
上周五，意大利制药公司Recordati S.p.A同意以总额82500万美元作为预付款，并向赛诺菲安万特(SNY)收购全球Enjaymo（sutimlimab）的权利，还包括最高25000万美元的商业里程碑支付。
Enjaymo, a humanized monoclonal antibody, is the only approved targeted product for cold agglutinin disease (CAD), a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis).
Enjaymo是一种人源化单克隆抗体，是唯一获批用于冷凝集素病（CAD）的靶向产品，这是一种罕见的自身免疫性疾病，其特征是红细胞（溶血）的过早破坏。
Also Read: FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease.
还阅读：FDA批准再生成/赛诺菲的亿美元抗击吸烟者肺病的Dupixent。
The FDA approved the drug in 2022. Administered as chronic IV treatment.
FDA于2022年批准该药。作为慢性静脉注射治疗。
Enjaymo generated approximately 100 million euros ($109.70 million) in revenue over the last 12 months as of August 2024 and is expected to generate revenue of over 150 million euros in fiscal 2025, with peak sales potential of 250 million-300 million euros, more than double current levels.
Enjaymo在截至2024年8月的过去12个月中产生了约10000万欧元（10970万美元）的营业收入，并预计在2025财年将产生超过15000万欧元的收入，销售潜力达到25000万-30000万欧元，是目前水平的两倍多。
Subject to the closing date, Recordati expects minimal revenue contribution in 2024. The transaction is expected to close by the end of 2024.
取决于交割日期，Recordati预计2024年对收入的贡献微乎其微。交易预计将在2024年年底前完成。
The transaction is expected to be immediately accretive at the EBITDA level, with the margin above the current Rare Diseases average as of 2025.
该交易预计在2025年EIBTDA层面立即实现增加，利润率高于截至2025年的当前罕见疾病平均水平。
The deal will be funded by existing cash and new committed bank debt facilities. Net debt is expected to be approximately 2.4 – 2.5x EBITDA (Pro-forma) at the end of 2024, de-leveraging to less than 2.0x EBITDA at the end of 2025, assuming no additional business development transactions.
该交易将由现有现金和新的承诺的银行债务设施资助。截至2024年底，净债务预计约为EBITDA（税前利润、税前利息、折旧和摊销前利润）的2.4-2.5倍，预计在2025年底降至低于EBITDA的2.0倍，假设没有额外的业务发展交易。
In September, Sanofi agreed to make a $27 million strategic investment in Ventyx Biosciences Inc. The company also agreed to grant Sanofi an exclusive right of first negotiation with respect to certain VTX3232 program rights.
赛诺菲安万特同意对Ventyx Biosciences Inc进行2700万美元的战略投资。该公司还同意授予赛诺菲对于特定VTX3232项目权益的独家首谈权。
Price Action: SNY stock is up 0.31% at $55.71 at last check Friday.
股价走势：SNY股价在上周五最后一次查询时上涨0.31%，达55.71美元。
Photo via Shutterstock
图片来自shutterstock。
- Rivian's Production Forecast Hits Bump, Supply Shortage Sends Shares Tumbling.
- Rivian的生产预测受挫，供应短缺导致股价下跌。